GI Innovation announced on April 9 that it plans to present two research findings at the American Association for Cancer Research Annual Meeting (AACR 2026), scheduled to take place in San Diego, USA, from April 17 to 22 (local time). At the conference, GI Innovation will present preclinical findings for ‘GI-128’ (development code), a novel pipeline derived from its proprietary ‘GI-SMART’ platform, along with pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation analysis results for its immuno-oncology candidate ‘GI-102’ (development code). https://www.thebionews.net/news/articleView.html?idxno=23518

GI Innovation announced on April 3 that Phase 1 clinical trial data for its immuno-oncology candidate, ‘GI-101A (development code),’ has been selected for a ‘Rapid Oral Abstract’ presentation at the American Society of Clinical Oncology Annual Meeting (ASCO 2026), widely regarded as the world’s most prestigious oncology conference. ASCO serves as a premier academic forum for the initial disclosure of the latest clinical data in the global oncology field and functions as a key venue for evaluating the clinical value of new therapeutics based on real-world patient data. https://www.thebionews.net/news/articleView.html?idxno=23367

GI Innovation has released modeling data on the dosing strategy for its immuno-oncology candidate, ‘GI-102’ (development code), demonstrating that fixed-dose administration can achieve immune activation effects comparable to those observed with body weight-based dosing. These findings have generated considerable interest, as they highlight the potential to move beyond the weight-based administration method traditionally required for Interleukin-2 (IL-2)-based therapies. https://www.thebionews.net/news/articleView.html?idxno=23000

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a phase 1b clinical trial. https://seekingalpha.com/pr/20445795-gi-innovation-announces-first-clinical-supply-agreement-to-explore-combination-therapy-for

“315 combination studies, 240 assets, 158 partners,” these figures illustrate the expansive ‘Keytruda ecosystem’ established by MSD (Merck, USA), a multinational pharmaceutical company that has reshaped the global immuno-oncology landscape. Since approval from the U.S. Food and Drug Administration (FDA) in September 2014, Keytruda has evolved into a global blockbuster immuno-oncology therapy, generating KRW 45.87 trillion (approximately USD 31.3 billion) in annual sales last year.https://www.thebionews.net/news/articleView.html?idxno=22527

GI Innovation has reaffirmed its commitment to establishing the global therapeutic potential of its bispecific fusion protein platform, which links CD80 and IL-2 variants to an IgG4 Fc, as an immuno-oncology treatment supported by robust clinical evidence. In particular, internal expectations are rising as its lead pipeline candidates, GI-101A (development code) and GI-102, have demonstrated encouraging clinical outcomes both as monotherapy and in combination with Keytruda, reinforcing their positioning in the global oncology landscape.https://www.thebionews.net/news/articleView.html?idxno=22526

GI Innovation reported that its subcutaneous (SC) formulation of the immunotherapy drug candidate ‘GI-102’ developed in-house has consistently demonstrated clinical efficacy in multiple trials conducted at leading U.S. medical institutions, including Memorial Sloan Kettering Cancer Center(MSK) and the Mayo Clinic. The previously reported case of ‘complete remission (CR)’ has remained tumor-free recurrence for six months, while a more recent case of ‘partial remission (PR)’ demonstrated an approximate 70% reduction in tumor burden in a patient with end-stage cancer. These clinical responses substantially strengthen the therapeutic value of the SC formulation of ‘GI-102’ as a novel drug candidate. On February 9, GI Innovation announced that a Phase 1b clinical trial evaluating GI-102 SC as a monotherapy achieved a ‘partial remission (PR)’ in patients with Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer. In an ongoing trial conducted at MSK, administration of GI-102 SC monotherapy (0.65 mg/kg) led to a 68% reduction in tumor lesion size within six weeks. https://www.thebionews.net/news/articleView.html?idxno=22125

GI Innovation is actively advancing efforts to expand the scope of its global Phase 2 clinical trial for its immuno-oncology candidate GI-101A. On January 30, GI Innovation announced in a public disclosure that it had submitted an amendment to the Investigational New Drug (IND) application for its Phase 1/2 clinical trial evaluating GI-101A as monotherapy and in combination with Keytruda (pembrolizumab) to the U.S. Food and Drug Administration (FDA). The amendment principally encompasses the adoption of the international nonproprietary name (INN) ‘efdelikofusp alfa,’ the introduction of a randomized study design for metastatic urothelial carcinoma, and the selection of Phase 2 target indications, including urothelial carcinoma, clear cell renal cell carcinoma, squamous cell non-small cell lung cancer, and microsatellite-stable (MSS) colorectal cancer. https://www.thebionews.net/news/articleView.html?idxno=21936

GI Innovation is actively advancing the development of a ‘next-generation allergy treatment’ optimized through the integration of artificial intelligence (AI) technologies. The company announced on January 20 that it has recently filed a patent application for a next-generation dual-fusion pipeline targeting atopic dermatitis. The next-generation dual-fusion allergy pipeline is engineered to concurrently inhibit the interleukin (IL)-4 and interleukin (IL)-13 signaling pathways, which are central mediators of allergic inflammation, while addressing the multifactorial pathophysiology of atopic dermatitis. In light of the competitive landscape, GI Innovation stated that it will refrain from disclosing additional details regarding other aspects of Dupixent's mechanism of action. https://www.thebionews.net/news/articleView.html?idxno=21625

On Tuesday, GI Innovation announced that it is ramping up development of a next-generation allergy treatment optimized using artificial intelligence (AI) technology. The company's novel dual fusion pipeline is designed to modulate the IL-4/IL-13 signaling pathway involved in allergic inflammation while simultaneously targeting the complex underlying causes of atopic dermatitis. Due to competitive considerations, GI Innovation has opted not to disclose specifics about mechanisms beyond that of Dupixent. The company initiated this pipeline over three years ago, beginning with the lead candidate GI-305, and has since made continuous structural improvements and functional validations. Notably, it has focused on enhancing antibody binding affinity, building on the same mechanism as Regeneron's blockbuster drug Dupixent, which generates annual sales of approximately $15 billion. https://en.news1.kr/lifestyle/5919552

GI Innovation is advancing the treatment of malignant brain tumors through an investigator-initiated clinical trial led by researchers at the Mayo Clinic, which ranked first in Newsweek's U.S. hospital rankings last year. The study is designed to assess the therapeutic potential of GI Innovation's bispecific Fc fusion protein, GI-102 (development code), administered either as monotherapy or in combination with MSD's immunotherapy Keytruda (pembrolizumab), in both neoadjuvant and adjuvant treatment settings. The clinical program targets high-grade malignant brain tumors, including glioblastoma and astrocytoma. https://www.thebionews.net/news/articleView.html?idxno=21401

This year's Nobel Prize in Physiology or Medicine was awarded to Professor Shimon Sakaguchi of Osaka University, in recognition of his groundbreaking discovery of regulatory T cells (Tregs), a finding that revolutionized the global paradigm of immune tolerance. Jang Myoung-ho, CEO of GI-Innovation and a former professor at the University of Osaka, who previously conducted research alongside Professor Sakaguchi, expressed deep emotion and admiration upon learning of the award. Over a decade ago, Jang co-authored a research paper with Sakaguchi [screenshot of the paper below] reflecting their shared contribution to the field of immunology. https://www.thebionews.net/news/articleView.html?idxno=18731